References
- Pratt C B. Ifosfamide studies for primary or recurrent pediatric malignant solid tumours and leukemia. Sent Oncol. 1990; 17: 31–40, suppl 4
- Goren M P, Wright R K, Horowitz M E, Pratt C B. Ifosfamide induced subclinical tubular nephrotoxicity despite Mesna. Cancer Treatm Rep. 1987; 71: 127–129
- Skinner R, Pearson A DJ, Price L, Coulthard M G, Craft A W. Nephrotoxicity after ifosfamide. Arch Dis Child. 1990; 65: 732–738
- Heney D, Wheeldon J, Rushworth P, Chapman C, Lewis I J, Bailey C C. Progressive renal toxicity due to ifosfamide. Arch Dis Child. 1991; 66: 966–970
- Pratt C B, Meyer W H, Jenkins J J, Avery L, McKay C P, Wyatt R J, Hancock M L. Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol. 1991; 9: 1495–1499
- Beetham R, Dawnay A, Landon J, Cattell W R. A radioimmunoassay for retinol binding protein in serum and urine. Clin Chem. 1985; 31: 1364–1367
- Caron H N, Abeling N, Van Gennip A, De Kraker J, Voute P A. Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing compounds. Med Pediatr Oncol. 1992; 20: 42–47
- Moncrieff M, Foot A. Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol. 1989; 23: 121–122
- Skinner R, Pearson A DJ, Price L, Cunningham K, Craft A W. Hypophosphataemic rickets after ifosfamide treatment in children. Br Med J. 1989; 298: 1560–1561
- Abeling N, De Kraker J, Van Gennip A. Abnormal plasma and urinary amino acid patterns in children on ifosfamide treatment. J Clin Ocol. 1987; 6: 48
- Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F. Long term follow up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumours: an International Society of Pediatric Oncology report. J Clin Oncol. 1991; 9: 2177–2182
- Goren M P, Wright R K, Pratt C B, Horowitz M E, Dodge R K, Viar M J, Kovnar E H. Potentiation of ifosfamide neurotoxicity and tubular nephrotoxicity by prior cis-diamine chlorproplatinum(II) therapy. Cancer Res. 1987; 47: 1457–1460
- Hadidi A HFA, Coulter C EA, Idle J R. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Res. 1988; 48: 5167–5171
- Stevens M CG, Brandis M. Ifosfamide nephrotoxicity: incidence and aetiology. Med Pediatr Oncol, in press